A study of AZD3470, a PRMT5 inhibitor, in patients with MTAP deficient advanced/metastatic solid tumors

Trial Identifier: D9970C00001
Sponsor: AstraZeneca
Start Date: January 2024
Primary Completion Date: February 2026
Study Completion Date: February 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
CN Beijing, CN, 100142
CN Chengdu, CN, 610041
CN Shanghai, CN, 200433
ES Barcelona, ES, 8035
ES Madrid, ES, 28027
FR Villejuif, FR, 94805
JP Chuo-ku, JP, 104-0045
JP Kashiwa, JP, 227-8577
KR seoul, KR, 06351
KR Seoul, KR, 03080
NL Amsterdam, NL, 1066CX
US, CA San Francisco, CA, US, 94143
US, CT New Haven, CT, US, 06510
US, MD Baltimore, MD, US, 21231
US, OR Portland, OR, US, 97239
US, PA Pittsburgh, PA, US, 15232
US, RI Providence, RI, US, 02903
US, VA Fairfax, VA, US, 22031